[1]董蕾,关晨阳,张莹,等.症状群信息化管理平台的建立及其在接受嵌合抗原受体T细胞免疫治疗淋巴瘤患者中的应用效果[J].新乡医学院学报,2023,40(2):169-173.[doi:10.7683/xxyxyxb.2023.02.014]
　DONG Lei,GUAN Chenyang,ZHANG Ying,et al.Establishment of symptom cluster information management platform and its application effect in lymphoma patients receiving chimeric antigen receptor T cell immunotherapy[J].Journal of Xinxiang Medical University,2023,40(2):169-173.[doi:10.7683/xxyxyxb.2023.02.014]
点击复制

症状群信息化管理平台的建立及其在接受嵌合抗原受体T细胞免疫治疗淋巴瘤患者中的应用效果
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
40卷
期数:
2023年2期
页码:
169-173
栏目:
护理研究
出版日期:
2023-02-05

文章信息/Info

Title:
Establishment of symptom cluster information management platform and its application effect in lymphoma patients receiving chimeric antigen receptor T cell immunotherapy
作者:
董蕾; 关晨阳; 张莹; 韩瑾; 张明智
（郑州大学第一附属医院肿瘤科,河南　郑州　450052）
Author(s):
DONG Lei; GUAN Chenyang; ZHANG Ying; HAN Jin; ZHANG Mingzhi
(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan Province,China)
关键词:
淋巴瘤; 嵌合抗原受体T细胞; 症状群; 信息化管理
Keywords:
lymphoma; chimeric antigen receptor T cell; symptom cluster; information management
分类号:
R473.73
DOI:
10.7683/xxyxyxb.2023.02.014
文献标志码:
A
摘要:
目的　建立症状群信息化管理平台并探讨其在接受嵌合抗原受体T细胞(CAR-T)免疫治疗淋巴瘤患者中的应用效果。
方法　采用便利抽样法选择2019年8月至2020年10月郑州大学第一附属医院河南省淋巴瘤诊疗中心收治的78例淋巴瘤患者为对照组，2020年11月至2021年12月收治的72例淋巴瘤患者为观察组。对照组患者给予常规护理干预。观察组患者在常规护理基础上使用症状群信息化管理平台。症状群信息化管理平台包括2个平台、4个端口、7个模块。分别于CAR-T输注前1 d及CAR-T输注后第1、3周，采用症状评估量表评估淋巴瘤患者症状严重程度。于患者出院当天，采用淋巴瘤患者生命质量测定量表评估患者的生命质量，使用郑州大学第一附属医院标准的护理满意度调查表调查患者对护理工作的满意度。
结果　2组患者症状评估量表评分比较差异有统计学意义（F组间=10.820，P<0.05）；2组患者不同时间点的症状评分量表评分比较差异有统计学意义（F时间=201.627，P<0.05）；不同护理方法和时间对2组患者的症状评估量表评分存在交互作用（F交互=44.293，P<0.05）；CAR-T输注前1 d，2组患者的症状评估量表评分比较差异无统计学意义（P>0.05）；CAR-T输注后第1、3周，观察组患者的症状评估量表评分显著低于对照组（P<0.05）。观察组患者的生命质量测定量表评分及护理满意度评分显著高于对照组（P<0.001）。
结论　症状群信息化管理平台可有效改善接受CAR-T免疫治疗淋巴瘤患者相关症状严重程度，提高生命质量及护理满意度。
Abstract:
Objective　To establish a symptom cluster information management platform and explore its application effect on lymphoma patients receiving chimeric antigen receptor T cells (CAR-T) immunotherapy.
Methods　A total of 78 lymphoma patients admitted to Henan Lymphoma Diagnosis and Treatment Center of the First Affiliated Hospital of Zhengzhou University from August 2019 to October 2020 were selected as the control group by the convenient sampling method,and 72 lymphoma patients admitted from November 2020 to December 2021 were selected as the observation group.The patients in the control group were given routine nursing intervention.The patients in the observation group used the symptom cluster information management platform on the basis of routine nursing.The symptom cluster information management platform includes 2 platforms,4 ports and 7 modules.The severity of symptoms of lymphoma patients was evaluated by Symptom assessment scale at 1 day before CAR-T infusion and 1 and 3 weeks after CAR-T infusion.On the day of discharge,the quality of life of patients was evaluated by the lymphoma patients′ quality of life inventory,and the nursing satisfaction of patients was investigated with the nursing satisfaction questionnaire of the First Affiliated Hospital of Zhengzhou University.
Results　There was significant difference in scores of symptom assessment scale of patients between the two groups (Finter-group=10.820,P<0.05);there was significant difference in scores of symptom assessment scale of patients in the two groups among different time points(Ftime=201.627,P<0.05);there was interaction of different nursing methods and time points on the score of symptom assessment scale of patients in the two groups (Finter-group=44.293,P<0.05);at 1 day before CAR-T infusion,there was no significant difference in the score of symptom assessment scale of patients between the two groups (P>0.05);at 1 and 3 weeks after CAR-T infusion,the score of symptom assessment scale of patients in the observation group was significantly lower than that in the control group (P<0.05).The scores of quality of life scale and nursing satisfaction of patients in the observation group were significantly higher than those in the control group (P<0.001).
Conclusion　The symptom cluster information management platform can effectively improve the severity of related symptoms of lymphoma patients receiving CAR-T immunotherapy,and improve the quality of life and nursing satisfaction.

参考文献/References:

［1］　BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］　XU H,CAO W,HUANG L,et al.Effects of cryopreservation on chimeric antigen receptor T cell functions［J］.Cryobiology,2018,83:40-47.
［3］　BRENJENS R J,RIVIERE I,PARK J H,et al.Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias［J］.Blood,2011,118(18):4817-4828.
［4］　金鑫,武日茂,赵明峰,等.供者来源CD19 CAR-T细胞在异基因造血干细胞移植后复发B细胞恶性肿瘤中的应用［J］.中华血液学杂志,2016,37(8):725-728.JIN X,WU R M,ZHAO M F,et al.Application of donor-derived CD19 CAR-T cells in recurrent B cell malignancies after allogeneic HSCT［J］.Chin J Hematol,2016,37(8):725-728.
［5］　刘畅,蒋婷,全诗翠,等.CAR-T技术的作用机制及其在恶性淋巴瘤中的应用［J］.重庆医学,2018,47(9):1242-1244.LIU C,JIANG T,QUAN S C,et al.The mechanism of action of CAR-T technology and its application in malignant lymphoma［J］.Chongqing Med,2018,47(9):1242-1244.
［6］　BRUDNO J N,SOMERVILLE R P,SHI V,et al.Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing Graft Versus-Host disease［J］.J Clin Oncol,2016,34(10):1112-1121.
［7］　克晓燕.嵌合抗原受体-T细胞免疫治疗在血液系统恶性肿瘤中的应用进展［J］.中国全科医学,2016,19(12):1361-1366．KE X Y.Application of CAR-T cell immunotherapy in the treatment of hematological malignancy［J］.Chin J Gen Prac,2016,19(12):1361-1366.
［8］　李玲,马建波.基于嵌合抗原受体的肿瘤免疫治疗的研究进展［J］.转化医学杂志，2015,4(2):97-104.LI L,MA J B.Advances in cancer immunotherapy based on chimeric antigen receptor［J］.Tran Med J,2015,4(2):97-104.
［9］　王雪莹,石琳,程志.嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤研究进展［J］.新乡医学院学报,2019,36(2):111-115．WANG X Y,SHI L,CHENG Z.Chimeric antigen receptor T cells in the treatment of hematological malignancies［J］.J Xinxiang Med Univ,2019,36(2):111-115.
［10］冯莉霞,冯丽娜,贺瑾.淋巴瘤患者症状评估量表的编制及信效度检验［J］.天津护理,2019,27(5):546-549.FENG L X,FENG L N,HE J.Developmentand validation of symptom assessment scale for lymphoma patients［J］.Tianjin Nurs,2019,27(5):546-549.
［11］　冯丽娜,冯莉霞,孟丽.中青年淋巴瘤化疗患者症状群的研究［J］.中华护理杂志,2017,52(12):1459-1463.FENG L N,FENG L X,MENG L.Symptom clusters in young and middle-aged lymphoma patients receiving chemotherapy［J］.Tianjin Nurs,2017,52(12):1459-1463.
［12］　NEELAPU S S,TUMMALA S,KEBRIAEI P,et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities［J］.Nat Rev Clin Oncol,2018,15(1):47-62.
［13］　KIM H J,BARSEVICK A M,TULMAN L.Predictors of the intensity of symptoms in a cluster in patients with breast cancer［J］.J Nurs Scholarsh,2009,41(2):158-165.
［14］　高月乔,张阳,陈长英.中文版淋巴瘤患者生命质量测定量表的信效度评价［J］.中国全科医学,2017,20(26):3277-3281.GAO Y Q,ZHANG Y,CHEN C Y.Reliability and validity of chinese version of functional assessment cancer therapy-lymphoma［J］.Chin J Gen Prac,2017,20(26):3277-3281.
［15］　何英剑,李晓婷,李金锋,等.大数据时代信息化管理平台在医院专科建设中的价值［J］.中国医院管理,2017,37(3):64-65.HE Y J,LI X T,LI J F,et al.Value of informationization management platform on hospital specialty construction in the era of big data［J］.Chin Hosp Manag,2017,37(3):64-65.
［16］　国家卫生计生委.全国护理事业发展划(2016-2020年)［J］.中国护理管理,2017,17(1):1-5.NATIONAL HEALTH AND FAMILY PLANNING COMMISSION.National nursing development plan (2016-2020)［J］.Chin J Nurs Manag,2017,17(1):1-5.
［17］　王语嫣,吴静,李楠楠,等.癌症病人症状群干预策略的研究进展［J］.护理研究,2020,34(2):273-278.WANG Y Y,WU J,LI N N,et al.Research progress of intervention strategies on symptom clusters of cancer patients［J］.Chin Nurs Res,2020,34(2):273-278.
［18］　刘春雪,张静.癌症患者症状群非药物干预方法研究进展［J］.中国护理管理,2017,17(11):1563-1566.LIU C X,ZHANG J.The non-pharmacological interventions for cancer patients′ symptom clusters:a review［J］.Chin Nurs Manag,2017,17 (11):1563-1566.
［19］　陈安,利兰久,王吉善.利用存在现象学定性研究患者满意度的体验元素［J］.中国卫生质量管理,2016,23(5):1-4.CHEN A,LI L J,WANG J S.A qualitative study on experience elements of patient satisfaction by using existential-phenomenology［J］.Chin Health Quality Manag,2016,23 (5):1-4.

相似文献/References:

[1]姜黄,杨广英,王玉香.胃肠道黏膜相关淋巴瘤27 例临床病理分析[J].新乡医学院学报,2010,27(06):606.
[2]王晓,常保萍,王瑞丽,等.蒽环类药物治疗弥漫大B细胞淋巴瘤中脑钠肽水平检测的临床意义[J].新乡医学院学报,2012,29(11):859.
[3]陈香丽,魏政洪,臧玉柱,等.克拉屈滨、吉西他滨、阿糖胞苷和白消安联合预处理方案在恶性淋巴瘤自体造血干细胞移植治疗中的疗效和安全性[J].新乡医学院学报,2022,39(12):1139.[doi:10.7683/xxyxyxb.2022.12.007]
　CHEN Xiangli,WEI Zhenghong,ZANG Yuzhu,et al.Efficacy and safety of combined pretreatment regimen of cladribine,gemcitabine,cytosine arabinoside and busulfan in autologous hematopoietic stem cell transplantation for malignant lymphoma[J].Journal of Xinxiang Medical University,2022,39(2):1139.[doi:10.7683/xxyxyxb.2022.12.007]
[4]卫延辉,郭学军.嵌合抗原受体T细胞治疗血液系统恶性肿瘤相关毒性机制研究进展[J].新乡医学院学报,2020,37(4):397.[doi:10.7683/xxyxyxb.2020.04.022]
[5]王雪莹,石　琳,程　志.嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤研究进展[J].新乡医学院学报,2019,36(2):111.[doi:10.7683/xxyxyxb.2019.02.003]

更新日期/Last Update: 2023-02-05